SPRUCE BIOSCIENCES, INC.
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
SPRB | US
Overview
Corporate Details
- ISIN(s):
- US85209E1091
- LEI:
- Country:
- United States of America
- Address:
- 611 GATEWAY BOULEVARD, SUITE 740, 94080 SOUTH SAN FRANCISCO
- Website:
- https://sprucebio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel, first-in-class therapies for serious and underserved neurological conditions. The company's lead investigational therapy, TA-ERT, is being advanced for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), also known as Sanfilippo Syndrome Type B. Guided by a patient-centric commitment, Spruce Biosciences aims to move beyond incremental progress by developing transformative treatments designed to deliver meaningful changes in patients' lives. The company seeks to challenge the current standard of care through data-driven innovation and empathy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all SPRUCE BIOSCIENCES, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SPRUCE BIOSCIENCES, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SPRUCE BIOSCIENCES, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
